Adynxx is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery and resolving established chronic pain conditions. Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom. Adynxx's lead compound, AYX1, is an investigational drug designed to reduce acute post-surgical pain and prevent the transition to persistent or chronic pain with a single administration at the time of surgery.

Key Contact